Advancing R&D for chronic diseases with AI: A conversation with Novo Nordisk’s CSO

Update: 2024-09-18

Description

Marcus Schindler, chief scientific officer, and head of research and early development at Novo Nordisk, shares the ways in which he's leading the company’s efforts to embrace external innovation and expand into new therapeutic areas with AI as a powerful catalyst for progress with McKinsey colleagues Alex Devereson and Nav Nagra.